Streetbeat News

NAVB

Navidea Biopharmaceuticals Inc

https://www.navidea.com/

CEO

Jed Latkin

Employees

Industry

Pharmaceutical Preparation Manufacturing

navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Navidea Biopharmaceuticals is facing a trading suspension as the NYSE American Panel has upheld its decision. The company anticipates moving to OTC Markets.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 6:53 am

The NYSE American has announced that it will suspend trading in Navidea Biopharmaceuticals (NAVB).

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 8:22 pm

During Tuesday's pre-market session, several healthcare stocks experienced significant movements. Longeveron Inc., Avinger, Navidea Biopharmaceutical, Elutia, ABVC BioPharma, and Akili saw increases in their shares, with Longeveron Inc. leading with a 172.7% increase. On the other hand, UpHealth, 60 Degrees, T2 Biosystems, SCWorx, Kinnate Biopharma, and MSP Recovery saw decreases in their shares, with UpHealth experiencing the largest decline of 50%.

Portfolio Pulse from Benzinga Insights

September 19, 2023 | 1:06 pm

During Thursday's pre-market session, several health care stocks experienced significant movement. Gainers included First Wave BioPharma, Avalo Therapeutics, TransCode Therapeutics, Navidea Biopharmaceutical, Longeveron Inc. - Subscription Right, and Evoke Pharma. Losers included Biolase, Bionomics, Scinai Immunotherapeutics, Impel Pharmaceuticals, ZyVersa Therapeutics, and Petros Pharma.

Portfolio Pulse from Benzinga Insights

September 14, 2023 | 1:06 pm

Several stocks experienced significant price movements in Wednesday's mid-day session. Eiger BioPharmaceuticals shares dropped by 52.5% after the company decided to discontinue a Phase 3 study. Avalo Therapeutics shares surged by 68% after receiving a notice from Nasdaq. Rocket Pharmaceuticals rose by 31.8% after reaching alignment with the FDA on a global Phase 2 trial. HireRight Holdings climbed by 14.8% after planning an additional $25 million share repurchase program. REV Group surged by 9.2% after reporting better-than-expected Q3 results and raising FY23 net sales guidance.

Portfolio Pulse from Lisa Levin

September 13, 2023 | 6:07 pm

During Thursday's intraday session, several healthcare stocks experienced significant movements. PhenomeX, Tivic Health Systems, Aditxt, Modular Medical, Salarius Pharmaceuticals, and AN2 Therapeutics saw increases in their share prices, with PhenomeX leading the gainers with a 136.4% increase. On the other hand, Fortress Biotech, Novo Integrated Sciences, Bioventus, Navidea Biopharmaceutical, T2 Biosystems, and Alaunos Therapeutics experienced decreases in their share prices, with Fortress Biotech leading the losers with a 24.5% decrease.

Portfolio Pulse from Benzinga Insights

August 17, 2023 | 5:31 pm

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Gainers included Novo Integrated Sciences (NVOS), Tivic Health Systems (TIVC), Navidea Biopharmaceutical (NAVB), Miromatrix Medical (MIRO), Catalyst Biosciences (CBIO), and Star Equity Hldgs (STRR). Losers included Impel Pharmaceuticals (IMPL), RVL Pharmaceuticals (RVLP), Mallinckrodt (MNK), Rockwell Medical (RMTI), G Medical Innovations (GMVD), and PAVmed (PAVM).

Portfolio Pulse from Benzinga Insights

August 16, 2023 | 5:31 pm

The article lists the stocks that gained and lost the most in Monday's trading session. Some of the notable gainers include Yellow Corporation, which saw its shares jump 106% after ceasing operations, and Archer Aviation, which climbed 41.8% after entering into contracts with the US Air Force. On the other hand, Apellis Pharmaceuticals fell 18.8% after reporting its quarterly financial results, and Alset Capital Acquisition Corp. shares fell 27.9%.

Portfolio Pulse from Lisa Levin

July 31, 2023 | 7:30 pm

Navidea Biopharmaceuticals Inc (NASDAQ:NAVB) shares have dropped by 18.5% to $0.08 after the company announced that NYSE American has started delisting proceedings. The company plans to appeal the decision and if delisted, Navidea intends to quote its common stock in the over-the-counter market.

Portfolio Pulse from Henry Khederian

July 31, 2023 | 1:39 pm

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) is focusing on advancing its technology to market and intends to appeal the potential delisting of its stock from the NYSE. The company has made several strategic changes, including reducing administrative expenses, promoting key personnel, and entering into various agreements to secure funding. It has also sold assets and launched a Strategic Partnership Initiative. Despite the potential delisting, Navidea sees opportunities for diverse capital sources and strategic agility. The company's clinical trials NAV3-32 and NAV3-33 are progressing, with the former nearing completion.

Portfolio Pulse from Happy Mohamed

July 31, 2023 | 1:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.